Table 2.
Treatment characteristics and cumulative toxicities analysis: only Grade 3-4 toxicities are reported (CTCAE version 4.0).
| Treatment characteristics | HDR-BT | RE | RFA | TACE | ivCTX | iaCTX |
|---|---|---|---|---|---|---|
| Patients (n) | 45 | 11 | 3 | 3 | 16 | 9 |
| Karnofsky index, median (range) |
80 (60–100) |
80 (60–90) |
90 (60–90) |
70 (70) |
70 (60–100) |
90 (80–90) |
| ECOG index, median (range) |
1 (0–2) |
1 (0–2) |
0 (0–2) |
1 (1-1) |
1 (0–2) |
0 (0-1) |
| Number of days hospitalized, median (range) | 4 (1–11) |
4 (3–5) |
5 (4–6) |
4 (3–6) |
0 | 0 |
| Total number of treatments/chemotherapeutic cycles (n) | 101 | 20 | 3 | 12 | 64 | 43 |
| Median number of treatments/chemotherapeutic cycles per patient (range) | 1 (1–5) |
1 (1–4) |
3 (1-1) |
4 (3–5) |
5 (1–12) |
6 (4–23) |
| Median RE-dose delivered (GBq), median (range) | — | 1.63 (0.9–2.55) |
— | — | — | — |
| Best response | CR | PR | CR | PD | SD | PR |
| Adverse events acc. CTCAE (highest grade recorded) | 3 | 2 | 2 | 1 | 3 | 2 |
| Abscess (n) | 1 | — | — | — | — | — |
| Shivering∗ (n) | 1 | — | — | — | — | — |
| Hematoma subcapsular (n) | 1 | — | — | — | — | — |
| Anemia (n) | — | — | — | — | 1 | — |
| Thrombopenia (n) | — | — | — | — | 1 | — |
| Neutropenia (n) | — | — | — | — | 1 | — |
| Anorexia (n) | — | — | — | — | 1 | — |
| Fatigue (n) | — | — | — | — | 2 | — |
| Pain (n) | — | — | — | — | 1 | — |
| Diarrhea (n) | — | — | — | — | 1 | — |
| Rash (n) | — | — | — | — | 1 | — |
Data are expressed as absolute number of events (n).
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. CTCAE, common toxicity criteria of adverse events.
∗Shivering due to radiation effects during HDR-BT with the need for abruption of the intervention.